A Hierarchical Structured Fiber Device Remodeling the Acidic Tumor Microenvironment for Enhanced Cancer Immunotherapy
Source abstract
Abstract
Abstract The acidic microenvironment of tumors significantly reduces the anti‐tumor effect of immunotherapy. Herein, a hierarchically structured fiber device is developed as a local drug delivery system for remodeling the acidic tumor microenvironment (TME) to improve the therapeutic effect of immunotherapy. Proton pump inhibitors in the fiber matrix can be sustainedly released to inhibit the efflux of intracellular H+ from tumor cells, resulting in the remodeling of the acidic TME. The targeted micelles and M1 macrophage membrane‐coated nanoparticles in internal cavities of fiber can induce immunogenic cell death (ICD) of tumor cells and phenotypic transformation of tumor‐associated macrophages (TAMs), respectively. The relief of the acidity in the TME further promotes ICD and the polarization of TAMs, alleviating the immunosuppressive microenvironment and synergistically enhancing the antitumor immune response. In vivo results reveal this local drug delivery system restores the pH value of TME from 6.8 to 7.2 and exhibit an excellent immunotherapeutic effect.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · 3D Printing in Biomedical Research · Nanowire Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Biomedical Engineering College of Medicine Southwest Jiaotong University Chengdu 610031 P. R. China
Key Laboratory of Advanced Technologies of Materials Ministry of Education School of Materials Science and Engineering Southwest Jiaotong University Chengdu 610031 P. R. China
Funding
National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities
References (53)
Show source-provided references
1. 10.1038/s41591-021-01233-910.1038/s41591-021-01233-9 ↗
2. 10.1126/scitranslmed.aat780710.1126/scitranslmed.aat7807 ↗
3. 10.1038/s41573-018-0006-z10.1038/s41573-018-0006-z ↗
4. 10.1002/adma.20200356310.1002/adma.202003563 ↗
5. 10.1021/acsnano.0c0707110.1021/acsnano.0c07071 ↗
6. 10.1021/acs.nanolett.1c0300410.1021/acs.nanolett.1c03004 ↗
7. 10.1002/adma.20210630710.1002/adma.202106307 ↗
8. 10.1146/annurev-physiol-021119-03462710.1146/annurev-physiol-021119-034627 ↗
9. 10.1038/s41577-021-00541-y10.1038/s41577-021-00541-y ↗
10. 10.1158/0008-5472.CAN-18-396210.1158/0008-5472.CAN-18-3962 ↗
11. 10.1093/annonc/mdw16810.1093/annonc/mdw168 ↗
12. 10.1038/s41392-020-00280-x10.1038/s41392-020-00280-x ↗
13. 10.1152/physrev.00035.201510.1152/physrev.00035.2015 ↗
14. 10.1038/s41467-022-30436-y10.1038/s41467-022-30436-y ↗
15. 10.1002/adma.20210652010.1002/adma.202106520 ↗
16. 10.1007/s40820-022-00894-610.1007/s40820-022-00894-6 ↗
17. 10.1016/j.chempr.2021.11.02010.1016/j.chempr.2021.11.020 ↗
18. 10.1038/nrc.2017.7710.1038/nrc.2017.77 ↗
19. 10.1016/j.nantod.2018.06.00810.1016/j.nantod.2018.06.008 ↗
20. 10.1038/nrgastro.2017.11710.1038/nrgastro.2017.117 ↗
21. 10.1016/j.semcancer.2017.01.00310.1016/j.semcancer.2017.01.003 ↗
22. 10.1002/adma.20160662810.1002/adma.201606628 ↗
23. 10.1038/s41467-018-03705-y10.1038/s41467-018-03705-y ↗
24. 10.1038/s41578-020-00269-610.1038/s41578-020-00269-6 ↗
25. 10.1039/C9CS00271E10.1039/C9CS00271E ↗
26. 10.1038/s41467-022-31579-810.1038/s41467-022-31579-8 ↗
27. 10.1021/acs.accounts.0c0034110.1021/acs.accounts.0c00341 ↗
28. 10.1016/j.nantod.2022.10140510.1016/j.nantod.2022.101405 ↗
29. 10.1016/j.cell.2016.12.02210.1016/j.cell.2016.12.022 ↗
30. 10.1002/adfm.20200485110.1002/adfm.202004851 ↗
31. Li X. · ACS Nano · 2022 · 16 · 4
32. 10.1016/j.cell.2020.02.00110.1016/j.cell.2020.02.001 ↗
33. 10.1038/s41590-022-01132-210.1038/s41590-022-01132-2 ↗
34. 10.1002/adhm.20210122210.1002/adhm.202101222 ↗
35. 10.1016/j.jconrel.2019.09.02110.1016/j.jconrel.2019.09.021 ↗
36. 10.1021/acs.nanolett.1c0020910.1021/acs.nanolett.1c00209 ↗
37. 10.1002/smll.20200354310.1002/smll.202003543 ↗
38. 10.1002/adfm.20180138910.1002/adfm.201801389 ↗
39. 10.1124/pr.58.3.1010.1124/pr.58.3.10 ↗
40. 10.1002/smll.20190226210.1002/smll.201902262 ↗
41. 10.1038/s41590-018-0226-810.1038/s41590-018-0226-8 ↗
42. 10.1038/s41571-021-00588-910.1038/s41571-021-00588-9 ↗
43. 10.1016/j.semcancer.2017.03.00110.1016/j.semcancer.2017.03.001 ↗
44. 10.1158/0008-5472.CAN-08-044910.1158/0008-5472.CAN-08-0449 ↗
45. 10.1126/sciadv.abi860210.1126/sciadv.abi8602 ↗
46. 10.1002/smll.20200697010.1002/smll.202006970 ↗
47. 10.1002/smll.20200490510.1002/smll.202004905 ↗
48. 10.1038/s41590-018-0258-010.1038/s41590-018-0258-0 ↗
49. 10.1038/ncomms1319310.1038/ncomms13193 ↗
50. 10.1002/adfm.20201063710.1002/adfm.202010637 ↗
51. 10.1038/s41467-022-30543-w10.1038/s41467-022-30543-w ↗
52. 10.1038/nrd355410.1038/nrd3554 ↗
53. 10.1038/s41392-022-00922-210.1038/s41392-022-00922-2 ↗